Business Context and Reporting Period
Company: GlaxoSmithKline plc (GSK)
Filing Type: Form 6-K (Report of Foreign Issuer)
Reporting Period: December 21, 2017
Subject: FDA approval of US label updates for inhaled corticosteroid (ICS) / long-acting beta 2 agonist (LABA) combination medicines, specifically removing the boxed warning for asthma-related death risk.
Key Financial Metrics
This filing is a regulatory announcement regarding product safety and labeling. It does not contain financial statements, revenue figures, profit margins, cash flow data, debt levels, or liquidity metrics. The filing text does not provide a clear value for any financial indicators.
Material Changes
Regulatory Status Change: The US Food and Drug Administration (FDA) approved the removal of the "boxed warning" from the labels of ICS/LABA combination products, including BREO ELLIPTA, ADVAIR DISKUS, and ADVAIR HFA.
Scientific Basis: The decision follows a Post-Marketing Requirement issued in 2010. GSK submitted data from two large-scale, randomized, double-blind safety trials (AUSTRI for adults/adolescents and VESTRI for children aged 4-11).
Study Findings: The trials demonstrated that the addition of LABA to ICS therapy was non-inferior to ICS therapy alone regarding the risk of serious asthma-related events (death, intubation, or hospitalization). No excess risk was associated with salmeterol when used in combination with fluticasone propionate.
Outlook, Risks, and Management Commentary
Management Commentary: GSK highlighted its 50-year leadership in respiratory medicine and its commitment to developing innovative medicines to address unmet patient needs. The company emphasized a strategy of targeting underlying disease-driving biological processes.
Risks and Contingencies: While the boxed warning was removed, the updated labels retain significant warnings and precautions, including:
- Contraindications: Not for primary treatment of status asthmaticus or acute episodes requiring intensive measures.
- Cardiovascular Effects: Potential for clinically significant effects (pulse rate, blood pressure, arrhythmias) requiring caution in patients with cardiovascular disorders.
- Infection Risks: Risk of worsening tuberculosis, fungal, bacterial, viral, or parasitic infections; oropharyngeal candidiasis.
- Adrenal Insufficiency: Deaths have occurred during transfer from systemic to inhaled corticosteroids; tapering is required.
- Drug Interactions: Strong CYP3A4 inhibitors (e.g., ritonavir, ketoconazole) are not recommended due to increased systemic corticosteroid exposure.
Investor Verification Checklist
- Verify the full text of the updated US Prescribing Information for ADVAIR and BREO ELLIPTA on the FDA or GSK website.
- Review the published results of the AUSTRI and VESTRI studies in the New England Journal of Medicine (NEJM) to confirm the non-inferiority margins and confidence intervals.
- Assess the potential impact of the label update on market share and competitive positioning against other respiratory therapies.
- Monitor for any future FDA communications regarding the safety of LABA-containing medicines in pediatric populations.
- Check GSK's Annual Report on Form 20-F for detailed financial performance and principal risks not covered in this specific announcement.